Abstract
Castleman disease, or angiofollicular lymph node hyperplasia, is a rare benign lymphoproliferative disorder. We report an uncommon case of retroperitoneal Castleman syndrome associated with adrenal hyperandrogenism and with interleukin-6 as the possible link in the pathophysiology of both disturbances. Four years after surgical resection of the paraadrenal mass, the patient is free of signs of recurrence of Castleman disease and adrenal hyperandrogenism.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Irsutti M, Paul JL, Selves J, Railhac JJ. Castleman disease: CT and MR imaging features of a retroperitoneal location in association with paraneoplastic pemphigus. Eur Radiol 1999, 9: 1219–21.
Debatin J F, Spritzer CE, Dunnick NR. Castleman disease of the adrenal gland: MR imaging features. AJR Am J Roentgenol 1991, 157: 781–3.
Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 1981, 29: 577–80.
Azziz R, Bradley EL Jr, Potter HD, Boots LR. Adrenal androgen excess in women: lack of a role for 17-hydroxylase and 1 7,20-lyase dysregulation. J Clin Endocrinol Metab 1 995, 80: 400–
Papanicolaou DA, Wilder RL, Manolagas SC, Chrousos GP. The pathophysiologic roles of interleukin-6 in human disease. Ann Intern Med 1998, 128: 127–37.
Tsigos C, Papanicolaou DA, Defensor R, Mitsiadis CS, Kyrou I, Chrousos GP. Dose effects of recombinant human interleukin-6 on pituitary hormone secretion and energy expenditure. Neuroendocrinology 1997, 66: 54–62.
Mastorakos G, Weber JS, Magiakou MA, Gunn H, Chrousos GP. Hypothalamic-pituitary-adrenal axis activation and stimulation of systemic vasopressin secretion by recombinant interleukin-6 in humans: potential implications for the syndrome of inappropriate vasopressin secretion. J Clin Endocrinol Metab 1994, 79: 934–9.
van Gool J, van Vugt H, Helle M, Aarden LA. The relation among stress, adrenalin, interleukin 6 and acute phase proteins in the rat. Clin Immunol Immunopathol 1990, 57: 200–10.
Papanicolaou DA, Tsigos C, Oldfield EH, Chrousos GP. Acute glucocorticoid deficiency is associated with plasma elevations of interleukin-6: does the latter participate in the symptomatology of the steroid withdrawal syndrome and adrenal insufficiency? J Clin Endocrinol Metab 1996, 81: 2303–6.
Lyson K, McCann SM. The effect of interleukin-6 on pituitary hormone release in vivo and in vitro. Neuroendocrinology 1991, 54: 262–6.
Mastorakos G, Chrousos GP, Weber JS. Recombinant interleukin-6 activates the hypothalamic-pituitary-adrenal axis in humans. J Clin Endocrinol Metab 1993, 77: 1690–4.
Naitoh Y, Fukata J, Tominaga T, et al. Interleukin-6 stimulates the secretion of adrenocorticotropic hormone in conscious, freely-moving rats. Biochem Biophys Res Commun 1988, 155: 1459–63.
Salas MA, Evans SW, Levell MJ, Whicher JT. Interleukin-6 and ACTH act synergistically to stimulate the release of corticosterone from adrenal gland cells. Clin Exp Immunol 1990, 79: 470–3.
Päth G, Bornstein SR, Ehrhart-Bornstein M, Scherbaum WA. Interleukin-6 and the interleukin-6 receptor in the human adrenal gland: expression and effects on steroidogenesis. J Clin Endocrinol Metab 1997, 82: 2343–9.
Yoshizaki K, Matsuda T, Nishimoto N, et al. Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman’s disease. Blood 1989, 74: 1360–7.
Kishimoto T, Akira S, Narazaki M, Taga T. Interleukin-6 family of cytokines and gp130. Blood 1995, 86: 1243–54.
Peterson BA, Frizzera G. Multicentric Castleman’s disease. Semin Oncol 1993, 20: 636–47.
Brandt SJ, Bodine DM, Dunbar CE, Nienhuis AW. Dysregulated interleukin 6 expression produces a syndrome resembling Castleman’s disease in mice. J Clin Invest 1990, 86: 592–9.
Leger-Ravet MB, Peuchmaur M, Devergne O, et al. Interleukin-6 gene expression in Castleman’s disease. Blood 1991, 78: 2923–30.
Mandler RN, Kerrigan DP, Smart J, Kuis W, Villiger P, Lotz M. Castleman’s disease in POEMS syndrome with elevated interleukin-6. Cancer 1992, 69: 2697–703.
Adelman HM, Cacciatore ML, Pascual JF, Mike JM, Alberts WM, Wallach PM. Case report: Castleman disease in association with POEMS. Am J Med Sci 1994, 307: 112–4.
Papanicolaou DA, Petrides JS, Tsigos C, et al. Exercise stimulates interleukin-6 secretion: inhibition by glucocorticoids and correlation with catecholamines. Am J Physiol 1996, 271: E601–5.
Azziz R, Carmina E, Sawaya ME. Idiopathic hirsutism. Endocr Rev 2000, 21: 347–62.
Mowszowicz l, Melanitou E, Doukani A, Wright F, Kuttenn F, Mauvais-Jarvis P. Androgen binding capacity and 5 alpha-reductase activity in pubic skin fibroblasts from hirsute patients. J Clin Endocrinol Metab 1983, 56: 1209–13.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Müssig, K., Gallwitz, B., Machicao, F. et al. Paraadrenal Castleman disease presenting with adrenal hyperandrogenism. J Endocrinol Invest 29, 172–176 (2006). https://doi.org/10.1007/BF03344093
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03344093